Last reviewed · How we verify
ATX-MS-1467
ATX-MS-1467 is a peptide-based immunotherapy Biologic drug developed by Apitope Technology (Bristol) Ltd.. It is currently in Phase 2 development for Relapsing-remitting multiple sclerosis. Also known as: M2736, IL-10 Inducer.
ATX-MS-1467 is a peptide-based immunotherapy targeting myelin-associated glycoprotein (MAG) to treat multiple sclerosis.
ATX-MS-1467 is a small molecule being studied for the treatment of Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis. It is being evaluated in a proof of concept trial to assess its safety.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ATX-MS-1467 |
|---|---|
| Also known as | M2736, IL-10 Inducer |
| Sponsor | Apitope Technology (Bristol) Ltd. |
| Drug class | peptide-based immunotherapy |
| Target | myelin-associated glycoprotein (MAG) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
ATX-MS-1467 works by inducing tolerance to MAG, a protein that is targeted by autoreactive T cells in multiple sclerosis. This approach aims to reduce inflammation and halt disease progression. By modulating the immune response, ATX-MS-1467 has the potential to provide long-term disease control.
Approved indications
- Relapsing-remitting multiple sclerosis
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- ATX-MS-1467 in Multiple Sclerosis (PHASE2)
- ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATX-MS-1467 CI brief — competitive landscape report
- ATX-MS-1467 updates RSS · CI watch RSS
- Apitope Technology (Bristol) Ltd. portfolio CI
Frequently asked questions about ATX-MS-1467
What is ATX-MS-1467?
How does ATX-MS-1467 work?
What is ATX-MS-1467 used for?
Who makes ATX-MS-1467?
Is ATX-MS-1467 also known as anything else?
What drug class is ATX-MS-1467 in?
What development phase is ATX-MS-1467 in?
What are the side effects of ATX-MS-1467?
What does ATX-MS-1467 target?
Related
- Drug class: All peptide-based immunotherapy drugs
- Target: All drugs targeting myelin-associated glycoprotein (MAG)
- Manufacturer: Apitope Technology (Bristol) Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Relapsing-remitting multiple sclerosis
- Also known as: M2736, IL-10 Inducer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing